Prevalence of HBV in Pregnancy

Status Recruiting

Clinical Trial Summary

The most common mode of HBV transmission is materno-fetal transmission mainly during labor. This study aims to estimate the seroprevalence of HBV infection and the possible risk factors of HBV acquisition in pregnant women in Upper Egypt and to evaluate the predictive value of HBeAg and quantitative HBsAg as surrogate markers for high viremia in pregnant women.

Clinical Trial Description

Hepatitis B virus (HBV) is a cause of a vaccine-preventable life-threatening infection of the liver. Worldwide, the estimated number of cases of chronic HBV infection is 296 million cases with about 820 000 deaths, mostly due to liver cirrhosis and hepatocellular carcinoma. The prevalence of HBV infection among pregnant women is estimated to be 1.5-9.5%. The most important risk factor of materno-fetal transmission is high viremia. Other factors include hepatitis B e antigen (HBeAg) seropositivity, HBV S variant, and threatened preterm labor. Quantitative hepatitis B surface antigen (HBsAg) was postulated as a surrogate marker for HBV high viremia in pregnant women by many authors. This study aims to estimate the seroprevalence of HBV infection and the possible risk factors of HBV acquisition in pregnant women in Upper Egypt and to evaluate the predictive value of HBeAg and quantitative HBsAg as surrogate markers for high viremia in pregnant women. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05442372
Study type	Observational
Source	Sohag University
Contact	Amira Maher, MD
Phone	01006789652
Email	amiramaher@med.sohag.edu.eg
Status	Recruiting
Phase
Start date	June 15, 2022
Completion date	April 15, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01182311` - Duration of Long-term Immunity After Hepatitis B Virus Immunization
Completed	`NCT04971928` - Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment	Phase 1
Completed	`NCT03285620` - A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants	Phase 1
Completed	`NCT01884415` - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis	Phase 3
Recruiting	`NCT05404919` - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates	Phase 2
Completed	`NCT02153320` - Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers	Phase 1
Completed	`NCT00352963` - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).	Phase 3
Completed	`NCT03567382` - Arresting Vertical Transmission of Hepatitis B Virus	Phase 4
Not yet recruiting	`NCT04056728` - A Phase IV Study to Assess the Safety of EupentaTM Inj	Phase 4
Not yet recruiting	`NCT03604016` - Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver	Phase 4
Completed	`NCT00753649` - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants	Phase 4
Recruiting	`NCT03027258` - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome	N/A
Completed	`NCT02540538` - Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders	Phase 1
Terminated	`NCT02604199` - A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection	Phase 2
Completed	`NCT02169674` - Hepatitis B Booster Study in Adolescence	Phase 4
Completed	`NCT02421666` - A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV	N/A
Completed	`NCT01917357` - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject	Phase 3
Completed	`NCT01732354` - Study for Consolidation Period of Chronic Hepatitis B
Completed	`NCT01368497` - Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection	Phase 3
Recruiting	`NCT01462981` - Cohort of Hepatitis B Research of Amsterdam	N/A